List view / Grid view
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
24 January 2014 | By Daiichi Sankyo Company
Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products...
24 January 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients...
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
23 January 2014 | By Pfizer Inc
Pfizer Inc. announced top-line results from a Phase 3 study of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain...
22 January 2014 | By Johnson & Johnson
Janssen global public health to oversee R&D and access strategy development for growing portfolio of transformational medicines...
22 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union...
21 January 2014 | By kdm communications limited
Spanish biotechnology company Midatech Biogune is taking advantage of Syrris Atlas Potassium reactor systems to produce custom-made functionalized gold nanoparticles for medicinal use...
21 January 2014 | By Roche
Roche announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints...
21 January 2014 | By BMG Labtech
A team of world leaders in the growing scientific field of biomolecular interaction, relating to basic biomedical research and the discovery of new pharmaceuticals, has been the recipient of a new Australian Research Council Linkage Grant...
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
20 January 2014 | By OPTIMA Pharma
Stephan Reuter is the new CEO of OPTIMA pharma GmbH in Mornshausen, a worldwide known manufacturer of high quality innovative freeze-drying systems for the pharmaceutical and biotechnology industries...
